Flick Gocke Schaumburg advises SARSTEDT on investment in Smart4Diagnostics
Bonn, 2 August 2021 – Flick Gocke Schaumburg has advised SARSTEDT AG & Co. KG, a leading medical technology producer of consumables and equipment for diagnostic and scientific applications, on the strategic investment in the Munich based start-up Smart4Diagnostics GmbH as part of a Series A funding round.
SARSTEDT and the EIC Fund, established in 2020 by the European Commission for direct equity investment in breakthrough technologies, acted as the lead investors of the investor round. In addition to the two lead investors, existing investors also increased their shareholdings.
Advisors SARSTEDT AG & Co. KG: Flick Gocke Schaumburg (Bonn)
Partner: Dr Stephan Göckeler; Associate: Alexander Heinen (both Private Equity and Venture Capital, Bonn)
Smart4Diagnostics, based in Munich-Obersendling, was founded in 2018 as part of the EIT Health Wild Card programme and focusses on digitising the whole preanalytical process associated with blood sample collection. The “digital human blood sample fingerprint” developed by Smart 4 Diagnostics guarantees a complete data-picture for all quality aspects of human blood samples, from collection to their arrival at the laboratory. The transport of the samples is digitally tracked with high precision and temperature, and vibrations and transport time are also recorded. The data is automatically transferred to the laboratory information system (LIS) upon sample arrival at the laboratory.
SARSTEDT, known as a world market leader in the development of blood collection systems, and Smart4Diagnosticis will now work together to optimise the preanalytical process and the sample quality as a basis for decision making, enabling faster and more precise patient treatment. The partnership with Smart4Diagnostics SARSTEDT’s offers customers new ways of ensuring sample quality from sample collection to arrival in the laboratory.